Cemiplimab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cemiplimab: From an Anti-PD-1 Antibody to Gallbladder Adenosquamous Carcinoma
One-Sentence Summary
Cemiplimab (brand name LIBTAYO) is a marketed anti-PD-1 antibody, and the source data do not list its approved indication. The TxGNN model predicts it may be effective for gallbladder adenosquamous carcinoma, but 0 clinical trials and 0 publications currently support this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Gallbladder adenosquamous carcinoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761097) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Cemiplimab is an anti-PD-1 antibody, so it blocks the PD-1 immune checkpoint and may restore T-cell activity against tumours. This class of drugs is generally used for cancers that respond to immune checkpoint blockade.
Gallbladder adenosquamous carcinoma is a rare biliary tumour. The link to cemiplimab rests only on the TxGNN prediction score. No trial or publication was supplied, and the similarity to the original indication has not been assessed. The prediction is a hypothesis for follow-up, not evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Other Predicted Indications (for reference)
| Rank | Predicted Indication | Score | Evidence Level | Pack Recommendation |
|---|---|---|---|---|
| 2 | Glottis squamous cell carcinoma | 99.99% | L5 | Research Question |
| 3 | Rectal cloacogenic carcinoma | 99.99% | L5 | Hold |
| 4 | External ear basal cell carcinoma | 99.99% | L4 | Research Question |
| 5 | Adenosquamous prostate carcinoma | 99.99% | L5 | Hold |
| 6 | Urethral verrucous carcinoma | 99.99% | L5 | Hold |
| 7 | Lung occult squamous cell carcinoma | 99.99% | L5 | Hold |
| 8 | Pancreatic adenosquamous carcinoma | 99.99% | L5 | Hold |
| 9 | Non-keratinizing sinonasal squamous cell carcinoma | 99.99% | L5 | Research Question |
| 10 | Supraglottis squamous cell carcinoma | 99.99% | L5 | Research Question |
Only external ear basal cell carcinoma has any literature: a 2021 case report (PMID 34157152, Clin Exp Dermatol) describing a lasting response after stopping cemiplimab in one patient with locally advanced basal cell carcinoma. It is a single-patient observation and does not confirm the ear site or efficacy across patients. The head and neck squamous carcinoma predictions (ranks 2, 9, 10) are biologically plausible and worth a targeted evidence search.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| BLA761097 | LIBTAYO (Regeneron Pharmaceuticals, Inc.) | Injection |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-PD-1 antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction is supported only by the model score (Evidence Level L5). There are no trials, no literature, and no mechanism data. This is not enough to advance it, though the anti-PD-1 rationale is plausible.
To proceed, the following is needed:
- A targeted trial and literature search for gallbladder adenosquamous carcinoma, and for the higher-plausibility squamous and basal cell subsites
- Mechanism of action data (from DrugBank)
- The approved indication and the package insert warnings and contraindications (from the FDA label)
- An assessment of route compatibility and similarity to the original indication (both currently pending)
This report is for research reference only and is not medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.